In one study, monthly respiratory syncytial virus immune globulin (
RSVIG) significantly decreased the number of AOM episodes due to RSV, the most important viral etiologic agent.
Because of the cost of RSV-IG, and because viral transmission is possible when any blood product is administered, careful consideration of which children should receive RSVIG is warranted.
Groothius, J.R., Levin, M.J., Rodriguez, W., Hall, C.B., Long, C.E., Kim, H.W., Lauer, B.A., Hemming, V.G., & The RSVIG Study Group.